GlassScriptPhysician profile
Jacob Gaines
NPI 1437835907
$1,703.48
in general payments reported to CMS, 2019-2025
11 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $204 · 2024: $786 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.49 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $563.16 | 2023-2025 | Ams 700, Lithovue, Lithoclast |
| Photocure INC | $193.66 | 2024-2025 | Cysview |
| Janssen Biotech, INC. | $171.16 | 2024 | Erleada |
| Coloplast Corp | $160.39 | 2025 | |
| Janssen Scientific Affairs, LLC | $151.87 | 2024-2025 | Erleada |
| Teleflex LLC | $148.23 | 2024 | Urolift |
| Urogen Pharma, INC. | $131.24 | 2025 | |
| Astellas Pharma Global Development | $86.40 | 2025 | Xtandi |
| Tolmar, INC. | $44.97 | 2024-2025 | Jatenzo, Eligard |
| Corcept Therapeutics | $28.45 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $23.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.